(NASDAQ: IMDX) Insight Molecular Diagnostics's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 22.79%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 69.28%.
Insight Molecular Diagnostics's earnings in 2026 is -$47,841,000.On average, 6 Wall Street analysts forecast IMDX's earnings for 2026 to be -$26,842,816, with the lowest IMDX earnings forecast at -$27,530,596, and the highest IMDX earnings forecast at -$25,767,553. On average, 6 Wall Street analysts forecast IMDX's earnings for 2027 to be -$28,563,882, with the lowest IMDX earnings forecast at -$32,244,961, and the highest IMDX earnings forecast at -$25,089,460.
In 2028, IMDX is forecast to generate -$26,019,417 in earnings, with the lowest earnings forecast at -$24,999,047 and the highest earnings forecast at -$26,784,694.